Streetbeat News

LSDI

Lucy Scientific Discovery Inc

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

0.67

Mkt cap

907K

Volume

307K

High

0.67

P/E Ratio

-0.07

52-wk high

12.80

Low

0.48

Div yield

N/A

52-wk low

0.44

Lucy Scientific Discovery (LSDI) shares resumed trading after a circuit breaker halt. The halt was triggered due to significant price movement.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 2:56 pm

US stocks edged higher on Thursday with the Dow, NASDAQ, and S&P 500 all showing slight gains. Initial jobless claims fell by 10,000 to 222,000, better than market estimates. Notable stock movements include significant gains for Lucy Scientific Discovery Inc. (LSDI), Greenwave Technology Solutions, Inc. (GWAV), and TSR, Inc. (TSRI), while KULR Technology Group, Inc. (KULR), Spire Global, Inc. (SPIR), and Omeros Corporation (OMER) saw substantial declines.

Portfolio Pulse from Avi Kapoor

May 16, 2024 | 1:57 pm

Lucy Scientific Discovery shares resumed trading after a halt but were again halted due to a circuit breaker to the downside. Despite this, the stock is now up 245.1%.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 1:37 pm

The article highlights the pre-market movements of 12 health care stocks on Thursday. Significant gainers include Lucy Scientific Discovery (LSDI), SINTX Techs (SINT), Dynatronics (DYNT), Ontrak (OTRK), NovaBay Pharmaceuticals (NBY), and DBV Technologies (DBVT). Notable losers are Eyenovia (EYEN), NexImmune (NEXI), Monte Rosa Therapeutics (GLUE), Pieris Pharmaceuticals (PIRS), Strata Skin Sciences (SSKN), and SCWorx (WORX).

Portfolio Pulse from Benzinga Insights

May 16, 2024 | 12:06 pm

The article highlights the performance of 12 healthcare stocks during Wednesday's after-market session. Notable gainers include SINTX Techs (SINT), Petros Pharma (PTPI), and Bluejay Diagnostics (BJDX). Significant losers include Eyenovia (EYEN), Lucy Scientific Discovery (LSDI), and Monte Rosa Therapeutics (GLUE).

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 8:32 pm

Beckley Psytech and atai Life Sciences announced positive results from a Phase 2a study of 5-MeO-DMT for Treatment Resistant Depression. Utah hospitals will soon offer psilocybin and MDMA therapy. Elon Musk discussed the benefits of ketamine for depression and its positive impact on investors. Meta is under investigation for potentially facilitating illegal drug sales. MindMed's CEO highlighted LSD's potential in a podcast. Various companies and ETFs are mentioned with their stock performance.

Portfolio Pulse from Lara Goldstein

March 29, 2024 | 4:43 pm

Cybin Inc. received FDA Breakthrough Therapy designation for its psilocybin therapy for Major Depressive Disorder, alongside positive clinical data and a $150M private placement. MindMed also received the designation for its LSD-derived treatment for Generalized Anxiety Disorder, with expected proceeds of $175M from share offerings. Gilgamesh Pharmaceuticals was awarded a $14M grant for ibogaine analog research. Psyence Biomedical, Red Light Holland, and Clearmind Medicine were mentioned for their developments in psychedelics. The article also covered stock performances of several psychedelics companies.

Portfolio Pulse from Lara Goldstein

March 20, 2024 | 6:49 pm

In Monday's after-market session, several health care stocks showed significant movement. Ontrak, Universe Pharmaceuticals, and Augmedix were among the top gainers, with Ontrak leading at a 61.0% increase. Conversely, Acurx Pharmaceuticals, Acutus Medical, and Fresh2 Group were the top losers, with Acurx Pharmaceuticals experiencing a 16.6% decline. Notably, Augmedix and Acurx Pharmaceuticals released their Q4 earnings.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 9:33 pm

Jabil Inc. shares fell over 14% after reporting Q2 results and FY25 guidance below estimates. Other stocks also showed significant movement, with notable gainers including Verb Technology and Better Therapeutics, and losers like C3is Inc. and SELLAS Life Sciences.

Portfolio Pulse from Avi Kapoor

March 15, 2024 | 6:31 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Notably, Better Therapeutics (BTTX) surged by 65.4%, while SELLAS Life Sciences Gr (SLS) dropped by 28.7%. Other notable gainers include Carmell (CTCX) and P3 Health Partners (PIII), with increases of 38.52% and 38.23% respectively. On the losing end, Immuneering (IMRX) and Lucy Scientific Discovery (LSDI) saw declines of 28.45% and 25.64%. These movements reflect the volatile nature of healthcare stocks in the market.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.